Arai Y, Yoshki T, Okada K, Yoshida O, Yamamoto N, Sakatoku J, Sugimura Y, Kawamura J
Department of Urology, Faculty of Medicine, Kyoto University.
Hinyokika Kiyo. 1989 Sep;35(9):1519-28.
Serum prostatic specific antigen (PA), gamma-seminoprotein (gamma-Sm) and prostatic acid phosphatase (PAP) levels were measured in 113 untreated patients with prostatic cancer and in 137 patients with benign prostatic hypertrophy (BPH). We used a PA-TESTWAKO enzyme immunoassay kit, gamma-Sm enzyme immunoassay kit and PAP radioimmunoassay kit. Of the 113 patients, 81.4%, 73.5% and 69%, respectively, were detectable using a single assay. PA was more sensitive than the other two markers in all stages, especially in localized disease (stages A, B and C). Using the BPH group as a negative control, specificities of PA, gamma-Sm and PAP were 85.4%, 81.0% and 94.2%, respectively. Efficiency was, respectively, 81.2%, 79.6% and 82.8%. In the follow up period, 15 patients presented disease progression. At the time of clinical detectable progression, the sensitivities of PA and gamma-Sm were both 100% (15/15), while 67% (10/15) for PAP. Concerning the sensitivity within 6 months prior to progression, gamma-Sm and PA tended to be more sensitive than PAP in early detection of disease progression. This study shows that PA is more reliable than gamma-Sm and PAP in detecting and staging of prostatic cancer. gamma-Sm and PA appear to be more reliable in earlier prediction of disease progression.
我们检测了113例未经治疗的前列腺癌患者和137例良性前列腺增生（BPH）患者的血清前列腺特异性抗原（PA）、γ-精浆蛋白（γ-Sm）和前列腺酸性磷酸酶（PAP）水平。我们使用了PA-TESTWAKO酶免疫分析试剂盒、γ-Sm酶免疫分析试剂盒和PAP放射免疫分析试剂盒。在113例患者中，单项检测的可检测率分别为81.4%、73.5%和69%。在所有阶段，PA比其他两种标志物更敏感，尤其是在局限性疾病（A、B和C期）。以BPH组作为阴性对照，PA、γ-Sm和PAP的特异性分别为85.4%、81.0%和94.2%。效率分别为81.2%、79.6%和82.8%。在随访期间，15例患者出现疾病进展。在临床可检测到进展时，PA和γ-Sm的敏感性均为%（15/15），而PAP为67%（10/15）。关于进展前6个月内的敏感性，在疾病进展的早期检测中，γ-Sm和PA比PAP更敏感。这项研究表明，在前列腺癌的检测和分期中，PA比γ-Sm和PAP更可靠。γ-Sm和PA在疾病进展的早期预测中似乎更可靠。
